Within the very few genes showing under-expression in ERG-negative carcinomas with an even more marked fold-decrease in ERG-positive lesions, RBMS2 (nucleic acid binding protein) displayed a massive fold-change reduction, which we set out to validate (Figure S1D). Here, RBMS2 is linked to carcinoma.